AVN944 Elicits Apoptotic Responses and Impedes Tumorigenic Potential in Ewing's Sarcoma Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Inosine monophosphate dehydrogenase 2 (IMPDH2) is crucial for guanine nucleotide synthesis, supporting cancer cell survival and proliferation.
• Ewing's sarcoma is a challenging pediatric and young adult malignancy with limited treatment options.
• Targeting nucleotide biosynthesis pathways presents a potential therapeutic strategy for Ewing's sarcoma.

Purpose of the Study:

• To evaluate the efficacy of AVN944, an IMPDH2 inhibitor, as a potential treatment for Ewing's sarcoma.
• To investigate the association between IMPDH2 expression and patient survival in sarcoma.
• To assess the in vitro and in vivo effects of AVN944 on Ewing's sarcoma cells.

Main Methods:

• Analysis of The Cancer Genome Atlas (TCGA) gene expression and clinical data for sarcoma patients.
• In vitro studies using human Ewing's sarcoma cell lines (TC71, SK-ES-1) with assays for viability, proliferation, cell cycle, and apoptosis.
• In vivo efficacy and toxicity assessment in xenograft models of Ewing's sarcoma.

Main Results:

• High IMPDH2 expression trended towards poorer overall survival in sarcoma patients.
• AVN944 significantly reduced Ewing's sarcoma cell viability and proliferation in a dose-dependent manner, inducing G1 cell cycle arrest and apoptosis.
• AVN944 demonstrated effective tumor growth inhibition in vivo xenograft models with no significant toxicity; IC50 was ~0.05 μM.

Conclusions:

• AVN944 exhibits potent in vitro and in vivo anti-tumor activity against Ewing's sarcoma by inhibiting IMPDH2.
• The drug's mechanism involves cell cycle arrest and apoptosis, leading to reduced tumor viability and proliferation.
• Targeting nucleotide biosynthesis with AVN944 shows promise for Ewing's sarcoma treatment, warranting further clinical investigation.